Paclitaxel and Carboplatin Toxicity Management

Hematologic Toxicities

Grade 3-4 neutropenia occurs in 37-48% of patients, and Grade 3-4 thrombocytopenia occurs in 2.8-9.6% of patients, according to the National Comprehensive Cancer Network 1

Peripheral sensory neuropathy is the dose-limiting toxicity of paclitaxel, occurring in up to 47% of patients, and patients with pre-existing neuropathy or diabetes are at higher risk, as recommended by the National Comprehensive Cancer Network 2
Risk of peripheral neuropathy is particularly high when retreating within 12 months of prior paclitaxel-containing regimen due to cumulative neurotoxicity, as reported in Annals of Oncology 3

Patients experiencing severe life-threatening reactions should never receive the implicated agent again, and desensitization protocols must be used with each subsequent infusion, as recommended by the National Comprehensive Cancer Network 4
Infusion reactions are more common with paclitaxel, while true allergic reactions are more common with platinum agents, according to the National Comprehensive Cancer Network 4, 5

More severe GI toxicity occurs with cisplatin-containing regimens compared to carboplatin, and the risk of grade 3 venous thromboembolic events increases when combined with bevacizumab, as reported in Annals of Oncology 1, 6
Grade 2 hypertension occurs in 25% of patients with bevacizumab addition, as reported in Annals of Oncology 6

Liver and renal function tests should be assessed regularly, as recommended by the National Comprehensive Cancer Network 2

The National Comprehensive Cancer Network recommends that docetaxel/carboplatin regimens carry increased neutropenia risk compared to paclitaxel/carboplatin, and the intravenous paclitaxel/carboplatin regimen carries higher neuropathy risk than docetaxel/carboplatin 7

The American Heart Association notes that paclitaxel may induce bradycardia directly through Purkinje system effects or indirectly via Cremophor EL, and when combined with doxorubicin, paclitaxel significantly enhances cardiotoxicity by altering doxorubicin pharmacokinetics and increasing myocyte formation of doxorubicinol (the major toxic metabolite) 8

The National Comprehensive Cancer Network reports that the intraperitoneal paclitaxel/cisplatin regimen causes leukopenia, infection, fatigue, renal toxicity, abdominal discomfort, and neurotoxicity, with only 42% of women initially completing all 6 cycles due to toxicity 7
The National Comprehensive Cancer Network also notes that dose-dense paclitaxel (80 mg/m² on days 1, 8, 15 with carboplatin) increases anemia risk and overall toxicity, leading to higher discontinuation rates than standard 3-week schedules 7